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esponsibility of InstAbstract (E)-Methyl-4-aryl-4-oxabut-2-enoate (YH-8) is a novel PKnB protein kinase inhibitor with good
anti-tuberculosis activity. To evaluate its pharmacokinetics in rats, a sensitive and selective high performance
liquid chromatography–tandem mass spectrometric (LC–MS/MS) method has been developed and validated for
the quantiﬁcation of YH-8 in rat plasma for the ﬁrst time. Samples were pre-treated using a liquid–liquid
extraction with ethyl acetate and the chromatographic separation was performed on a C18 column by gradient
elution with methanol–water as the mobile phase. YH-8 was detected using a tandem mass spectrometer in
positive selected reaction monitoring (SRM) mode. Method validation revealed good linearity over the range of
1–500 ng/mL for YH-8 with a lower limit of quantiﬁcation (LLOQ) of 1 ng/mL. Intra- and inter-day precision of
YH-8 assay in rat plasma samples were 2.0%–6.8%, with accuracy of the method being 100.69%–106.18%.
Stability test showed that when spiked into rat plasma, YH-8 was stable for 12 h at room temperature, for up to
15 days at 70 1C, and after three freeze-thaw cycles. Extracted samples were found to be stable over 12 h in an
auto-sampler. The method was successfully applied to the pharmacokinetic study of YH-8 in rats after oral
administration at 100 mg/kg and 200 mg/kg.
& 2015 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1
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PKnB is one of the most important serine/threonine protein kinases
for Mycobacterium tuberculosis (TB) and its structure consists of
extracellular domain, intracellular domain and transmembrane
helixes1. The intracellular domain of PknB has the main activity
of the holoenzyme, and is able to autophosphorylate and combine
with ATP and its analogues2–5. PKnB plays an important role in
the growth of TB, and is necessary for survival of TB6–8. Change
of expression index or phosphorylation of PKnB can lead to
alteration of growth rate and morphology of TB, due to the defects
in cell wall synthesis and cell division8–11. Because of the
signiﬁcant differences between PKnB and the human protein
kinases, it is widely accepted as the drug target for anti-TB. To
date, several PKnB inhibitors have been reported, and some of
them have shown certain degree of anti-TB capability. Most of
these compounds are aminopyrimidines, aminoguanidines and
anthraquinones12–17.
YH-8, namely (E)-methyl-4-aryl-4-oxabut-2-enoate (Fig. 1), is
a representative of the small molecule class of unsaturated crotonic
acid derivatives. Previous studies have shown that YH-8 could
inhibit the activity of PKnB18, and the anti-TB activity of YH-8 is
signiﬁcantly higher than the reported PknB inhibitors of amino-
pyrimidines, aminoguanidines and anthraquinones classes, making
it a promising anti-TB candidate for further research12–18. Pre-
clinical pharmacokinetic characteristics can help to predict drug's
behavior in human body and thus concurring to its safe and
efﬁcient clinical application. However, no information about the
pharmacokinetics of YH-8 has been reported so far. Hence, it is
necessary to develop a robust assay for the pharmacokinetic study
of YH-8.
YH-8 is difﬁcult to be detected in plasma in virtue of its low
concentration. LC–UV has poor sensitivity and speciﬁcity for YH-
8 in plasma samples, so it cannot meet the requirements of the
measurement. LC–MS/MS has demonstrated to be the most
valuable tool for pharmacokinetic study because of its higher
sensitivity and speciﬁcity compared with other analytical tools,
such as HPLC–UV19–23. Therefore, the present study was to
establish and validate a sensitive, accurate and reliable LC-MS/MS
assay for routine analysis of YH-8 in rat plasma and to
characterize the pharmacokinetic proﬁle of YH-8 in rats. Further-
more, to the best of our knowledge, no any biological analytical
method for determination of YH-8 to characterize the pharmaco-
kinetic property has been reported so far.2. Experimental
2.1. Chemicals and reagents
YH-8 (purity498%) was synthesized and puriﬁed by Institute of
Medicinal Biotechnology, Chinese Academy of Medical Sciences
(Beijing, China). HPLC-grade methanol was purchased from
Fisher Scientiﬁc (New Jersey, USA). Ultrapure water was obtainedFigure 1 The chemical structure of YH-8.from a Millipore system (Bedford, USA). All other reagents were
of analytical grade. Nitrogen gas was provided by the Gas
Company of Beijing (China).
2.2. Instrumentation and conditions
A Finnigan Surveyor Plus HPLC system (Thermo Finnigan, San
Jose, USA), equipped with a quaternary pump, a vacuum degasser,
an auto-sampler and a column heater-cooler, was connected by an
electrospray ionization (ESI) interface to a Thermo Finnigan TSQ
Quantum mass spectrometer (Thermo Finnigan, San Jose, USA).
Samples were separated on a Waters XTerras MS C18 column
(50 mm 2.1 mm, 3.5 μm, Waters XTerras, Ireland) with the
column temperature set at 35 1C. The mobile phase consisting of
ultrapure water (A) and methanol (B) was delivered for separation
of analytes using a gradient elution program at a ﬂow rate of
0.3 mL/min. The gradient elution program was conducted as
follows: 0–5.0 min, 10% B; 5.0–6.0 min, 10%–50% B; 6.0–
14.0 min, 50% B; 14.0–14.01 min, 50%–10% B; 14.01–
16.0 min, 10% B. The auto-sampler was maintained at 4 1C and
the injection volume was 5 μL. Solvent eluted from chromato-
graphy column during the ﬁrst four minutes was switched to waste
before it entered the ion source. The MS was set in positive
selected reaction monitoring mode with the transition of m/z
221-161 for YH-8. The MS operating conditions were optimized
and set as follows: sheath gas pressure, 30 arbitrary units; auxiliary
gas pressure, 10 arbitrary units; capillary temperature, 350 1C;
spray voltage, 3800 V and source collision-induces dissociation
(CID), 15 V. The collision gas was argon and the collision energy
was 17 eV. Data were processed using Xcalibur software (Thermo
Finnigan, San Jose, USA).
2.3. Animals
Twelve Sprague–Dawley (SD) rats, weighing 180–220 g (Certiﬁ-
cate No. SCXK (Army) 2007-004), were supplied by Academy of
Military Medical Sciences (Beijing, China). The rats were housed
under controlled environmental conditions (temperature 2373 1C;
humidity, 55%–75%) with a commercial food diet and water freely
available. All animals were acclimated in the laboratory for at least
seven days prior to the experiments and fasted for 12 h but allowed
water ad libitum before experiments. Animal experiments were
carried out under the permission and supervision of the Ethics
Committee of Institute of Medicinal Biotechnology, Chinese
Academy of Medical Sciences and Peking Union Medical College,
Beijing, China.
2.4. Preparation of calibration standards and quality control
samples
Stock solution of YH-8 at 1.0 mg/mL was prepared by dissolving
appropriate weight of the compound in methanol. Aliquots of YH-8
stock solutions were further diluted with methanol to yield the
working standard solutions of 0.5, 5 and 50 μg/mL, respectively.
All of the solutions were stored at 4 1C. Calibration standards were
prepared by spiking blank rat plasma with working standard
solutions of YH-8, and the ﬁnal concentrations were 1, 2.5, 5,
10, 25, 50, 100, 250 and 500 ng/mL. Quality control (QC) samples
were prepared similarly, with ﬁnal concentrations of 2.5, 40 and
400 ng/mL, respectively. These samples were stored under the
same conditions as the experimental samples.
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Before analysis, plasma samples were thawed at room temperature
together with calibration standards and QC samples. A 100 μL
volume of the plasma sample was transferred into a 1.5 mL
centrifuge tube. The sample was extracted with 400 μL ethyl
acetate by vortex for 1 min. The sample was then centrifuged at
8000 rpm for 15 min and the supernatant was transferred to a new
tube. The residue was extracted one more time with 400 μL ethyl
acetate, and the supernatant was combined with the ﬁrst round
supernatant. These sample extracts were evaporated to dryness at
room temperature under a stream of nitrogen, reconstituted with
200 μL of mobile phase, vortexed for 1 min, ﬁltered through a
0.22 μm pore size ﬁlter (Millipore), and then 5 μL of the solution
was injected into the LC–MS/MS system.
2.6. Method validation
The proposed assay method was validated for selectivity, linearity,
accuracy, precision, recovery, stability and matrix effect according
to the standard guidelines24,25.
2.6.1. Selectivity
The selectivity of the method was evaluated by analyzing six
different sources of blank rat plasma, blank plasma spiked with
YH-8 at lower limit of quantiﬁcation (LLOQ) and a rat plasma
sample collected after oral administration of YH-8. No signiﬁcant
interfering peaks should be present at the retention time of YH-8.
2.6.2. Linearity
Linearity of the proposed method was assessed by spiking YH-8 in
drug-free rat plasma covering the range of 1–500 ng/mL. Calibra-
tion curves were constructed by weighted (1/x2) least squares
linear regression of the peak areas (y) of YH-8 versus the
concentration (x) in ng/mL. The LLOQ was established as the
lowest concentration of YH-8 in the calibration curve at which
precision was within 20% of the relative standard deviation (RSD)
and accuracy was between 80% and 120% of the theoretical value.
2.6.3. Precision and accuracy
Intra-day and inter-day accuracy and precision were assessed by
analyzing ﬁve replicates of QC standards at LLOQ and three
concentrations (2.5, 40 and 400 ng/mL) within the same day or on
three different days. The accuracy (%) was calculated as (mean
measured concentration/nominal concentration) 100, and the
precision was expressed by the RSD (%) at each concentration
level. The accuracies should be within 715%, and the precisions
should not exceed 15% at all QC levels except the LLOQ which
should not exceed 20%.
2.6.4. Extraction recovery and matrix effect
Extraction and matrix effect were evaluated by employing Matus-
zewski method26. The recovery of YH-8 was determined by
comparing the responses of the analytes from QC samples (2.5,
40 and 400 ng/mL) with analytes spiked in post-extracted blank rat
plasma at equivalent concentrations. The matrix effect was mea-
sured by comparing the responses obtained from post-extraction
blank rat plasma spiked samples with that of mobile phase spiked
with corresponding concentrations of YH-8. A recovery of Z70%
and a matrix effect between 80% and 120% with a variation below
15% are considered ideal.2.6.5. Stability
The stabilities of YH-8 in rat plasma were evaluated by analyzing
ﬁve replicates of plasma samples at concentrations of 2.5, 40 and
400 ng/mL after being exposed to different conditions, and
comparing the results with those obtained from freshly prepared
plasma samples. The long-term stability of YH-8 in rat plasma was
assessed by carrying out the experiment after 15 days of storage at
70 1C. Freeze and thaw stability was determined by thawing at
room temperature and then refreezing at 70 1C for 24 h for three
cycles. The short-term room temperature stability was examined
by keeping the QC plasma samples at room temperature for 12 h.
The post-preparative stability was evaluated by analyzing pro-
cessed QC samples stored in autosampler at 4 1C for 12 h. For all
experiments, mean concentrations should be within 715% of the
nominal values.2.7. Pharmacokinetic study
The 12 SD rats were acclimatized to the facilities for 7 days and
then were randomly allocated into two groups (three males and
three females for each group). The rats were fasted with free access
to water for 12 h prior to oral administration of YH-8 at doses of
100 and 200 mg/kg, respectively, and fasted for another 4 h
after administration. YH-8 suspensions were freshly prepared in
1% (w/v) sodium carboxymethyl cellulose (CMC-Na). Blood
samples of 0.3 mL were taken via the post-orbital venous plexus
vein at 0.167, 0.333, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 10, 12, 24, 48 and
60 h after oral administration. The blood sample was transferred
into a heparinized eppendorf tube, mixed gently, and then
centrifuged (5000 rpm, 15 min) to obtain 100 μL of plasma, which
was kept at 70 1C until analysis. Pharmacokinetic parameters of
YH-8 were calculated by WinNonlins (Version 6.1, Pharsight
Corp., Mountain View, USA) using non-compartmental model.
Data were expressed as mean7SD.3. Results and discussions
3.1. Optimization of LC–MS/MS conditions
To optimize MS/MS parameters, 1 μg/mL YH-8 solution was
directly infused into the mass spectrometer in both positive and
negative mode. The observed mass spectral response and signal
stability of YH-8 was higher in positive mode. The MS spectrum
was recorded. YH-8 showed the [MþH]þ ion at m/z 221. The
[MþH]þ ion was used as the precursor to select product ion formed
by CID. The strongest fragment for YH-8 was the ion at m/z 161.
The transition m/z 221-161 was then used to optimize the CID and
other MS parameters for YH-8. Various mobile phases and a
number of commercially available HPLC columns were evaluated
for the chromatographic behavior and the ionization response of
YH-8. The best response was obtained from methanol and water.
The gradient elution mode and a Waters XTerra MS C18 column
(50 mm 2.1 mm, 3.5 μm) were applied in chromatographic
separation, and they provided satisfactory chromatographic results
with minimal matrix effects. No signiﬁcant signal suppression or
enhancement was found using the current conditions. Liquid–liquid
extraction and protein precipitation were compared as methods of
sample preparation, and the former was chosen since it produced a
cleaner background. Ethyl acetate, diethyl ether and trichloro-
methane were investigated as extraction solvents, and ethyl acetate
Figure 3 The calibration curve for YH-8 over the concentration
range of 1–500 ng/mL in rat plasma.
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mental friendly.
3.2. Selectivity
The typical chromatograms of blank rat plasma, the LLOQ sample
and in vivo plasma sample after oral administration of YH-8 are
presented in Fig. 2. Compared to spiked plasma samples, all blank
plasma samples from six individual rats were found to be free from
interference of endogenous substances at the retention time of YH-8
in the SRM scan mode. The representative chromatogram of real
plasma samples showed similar chromatographic behavior to
spiked plasma samples. Obviously, no signiﬁcant endogenous
interference at the retention time of YH-8, indicating that the assay
was selective.
3.3. Linearity and LLOQ
The calibration curves were established by plotting the peak area versus
nominal concentration using least squares linear regression analysis with
a weighting factor of 1/x2. The calibration curve for YH-8 exhibited
good linearity over the concentration range of 1–500 ng/mL, with
correlation coefﬁcient (R2)40.99 (Fig. 3). The typical standard curve
was described by the equation y¼3679.19þ3158.49x, where y is the
peak area and x is the concentration of YH-8. According to FDA
guidelines, the deviation for the calculated concentrations from the
nominal concentrations should be within 15% with an exception of 20%
for the LLOQ. The accuracy and precision of calculated value at each
nominal concentration in this study was within the acceptable range.
Moreover, the LLOQ of YH-8 was 1.0 ng/mL with precision within
20% and accuracy between 80% and 120%.
3.4. Precision and accuracy
The precision and accuracy of the method were assessed using QC
samples (2.5, 40 and 400 ng/mL). Intra-day and inter-day precisions
were lower than 5.3% and lower than 6.8% respectively for theFigure 2 Chromatograms of YH-8 in selected reaction monitoring mode
LLOQ; (C) a plasma sample collected at 45 min after oral administrationdifferent QC levels studied. The accuracy of the method was found
to be 100.69%–106.18% for the three QC levels (Table 1). The
accuracies and precisions for the tested levels were all within the
deﬁned acceptance criteria, demonstrating that the method was
accurate and precise.3.5. Matrix effect and recovery
The mean matrix effects at the three QC concentrations (2.5, 40
and 400 ng/mL) were 89.21%, 89.91% and 86.42%, with the
variation coefﬁcient of 2.81%–6.32%. The data convincingly sug-
gested the absence of ion-suppression or ion-enhancement for YH-8.
The mean extraction recoveries of YH-8 from spiked rat plasma
under the liquid extraction conditions were 85.61%, 88.34% and
87.58% at concentrations of 2.5, 40 and 400 ng/mL, respectively,
with the variation coefﬁcient of 4.61%–7.13%. The recoveries of
all three QC levels are consistent, precise and reproducible,
indicating the suitability of liquid extraction procedures for
separation of YH-8 from rat plasma samples27.in matrix. (A) Blank rat plasma; (B) blank plasma spiked with YH-8 at
of YH-8 at 100 mg/kg to the rat.
Table 3 Mean plasma concentration-time proﬁle of YH-8 in
rats after oral administration at 100 and 200 mg/kg. Each point
and bar represents the mean7SD (n¼6).a
Pharmacokinetic
parameters
100 mg/kg 200 mg/kg
T1/2 (h) 7.1770.56 7.2170.57
Tmax (h) 0.6370.49 0.5870.46
Cmax (ng/mL) 289.72737.54 457.087109.77
AUC0 t (ng  h/mL) 1137.417167.62 2101.667270.92
AUC0–1 (ng  h/mL) 1148.467167.47 2119.457269.42
Vz/F (L/kg) 1028.077155.71 996.437163.73
CL/F (L  h/kg) 98.11716.03 95.66712.30
MRT (h) 11.7372.74 13.1173.18
aCmax: the maximum concentration; Tmax: the time to maximum
concentration; AUC0–t: area under curve from time zero to the last
sampling time; AUC0–1: area under curve from time zero to
Figure 4 Mean plasma concentration-time proﬁle of YH-8 in rats
after oral administration at 100 and 200 mg/kg. Each point and bar
represents the mean7SD (n¼6).
Table 2 Stability of YH-8 in rat plasma (n¼5; mean7SD).
Nominal concentration (ng/mL) Recovered (%)
Short-term (r.t., 12 h) Long-term (70 1C, 15 d) Freeze-thaw (3 cycles) Post-preparative (4 1C, 12 h)
2.5 100.8573.47 97.1778.44 92.9073.87 99.1774.48
40 101.3571.91 97.3074.02 95.0372.82 98.0275.12
400 101.1576.32 97.4879.13 93.2778.90 98.3877.23
Table 1 Precision and accuracy for the determination of YH-8 in rat plasma.
Nominal concentration
(ng/mL)
Intra-day accuracy
(%, n¼5)
Inter-day accuracy
(%, n¼15)
Intra-day precision
(RSD%, n¼5)
Inter-day precision
(RSD%, n¼15)
1 100.92 103.71 6.5 8.2
2.5 101.28 103.68 5.3 5.8
40 100.69 104.86 3.5 6.8
400 106.18 101.80 2.0 4.4
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The results for stability study of YH-8 (long-term storage, room
temperature storage, freeze-thaw cycles and post-preparation
storage) are shown in Table 2. For all experiments, mean
concentrations were within 715% of the nominal values. The
data demonstrated that YH-8 was stable in rat plasma stored at
70 1C for 15 days, at room temperature for 12 h and after three
freeze-thaw cycles. It was also stable in the ready-to-inject sample
placed in autosampler at 4 1C for 12 h. The stability was thus
satisfactory for a routine pharmacokinetic study.
3.7. Pharmacokinetic application
The validated assay method was successfully applied to the
pharmacokinetic study of YH-8 in rats following oral administra-
tion at 100 and 200 mg/kg. The bioanalytical method was sensitive
enough to quantify YH-8 concentration in plasma up to 60 h.
Pharmacokinetic data of YH-8 were processed with Phoenix
WinNonlin version 6.1 software simulating through non-
compartmental analysis. The mean plasma concentration proﬁle
is shown in Fig. 4 and mean pharmacokinetic parameters are
shown in Table 3. After oral administration at 100 and 200 mg/kg,
YH-8 rapidly reached peak level at about 0.6 h and eliminated
with elimination half-life of about 7.2 h without signiﬁcant
difference between the two doses. Both Cmax and AUC of YH-8
increased in a dose-dependent manner. The apparent volumes of
distribution (Vz/F) values were 1028.077155.71 and 996.437
163.73 L/kg for 100 and 200 mg/kg groups, indicating extensive
distribution of YH-8 into different organs and tissues. As YH-8 is
a lipophilic drug, and its concentration in the liver is much higher
than that in the kidney after oral administration (unpublished data),
the clearance (CL/F) values obtained suggested that YH-8 was
rapidly cleared via hepatic clearance. The pharmacokinetic proﬁle
of YH-8 in rats was characterized for the ﬁrst time.inﬁnity; T1/2: the plasma elimination half-life; MRT: mean resi-
dence time; CL: Clearance; Vz: volume of distribution; F: bioavai-
lability.4. Conclusions
In this study, a reliable, sensitive and speciﬁc LC–MS/MS method
for analysis of YH-8 in rat plasma was successfully developed and
validated, and used in pharmacokinetic study of YH-8 in rats. The
peaks obtained using the LC–MS/MS approach enabled thedetection of the analyte at very low concentration with high
resolution. A sample preparation method employing the liquid–
liquid extraction of YH-8 was also successfully developed. To our
Qianqian Zhai et al.472knowledge, this is the ﬁrst report of an LC–MS/MS method on the
determination of YH-8 in rats with a low detection limit. The
pharmacokinetic parameters of YH-8 in the present work enriched
our understanding of the pharmacologic features of YH-8, and
provided helpful information for its further development.
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